RFC
STML

Russell Frank Company’s Stemline Therapeutics, Inc. STML Stock Holding History

Russell Frank Company’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$66K Buy
+14,139
New +$69.1K ﹤0.01% 2833
2013
Q4 		– Sell
-18,068
Closed -$775K – 3182
2013
Q3 		$775K Sell
18,068
-10,782
-37% -$352K ﹤0.01% 2306
2013
Q2 		$688K Buy
+28,850
New +$459K ﹤0.01% 2217

Other funds holding STML

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Russell Frank Company's STML Position: Q1 2016 in Review

Russell Frank Company opened a new position in Stemline Therapeutics, Inc. (STML) in Q1 2016: 14,139 shares worth $66K. The stake represents ﹤0.01% of the portfolio and ranks #2833 among its holdings. This is a return to the name: Russell Frank Company previously reported a position in STML as recently as Q3 2013.

Russell Frank Company first reported a position in STML in Q2 2013 and has held it in 3 quarters since. The position peaked at $775K in Q3 2013. 63 funds tracked by Wall St. Rank hold STML as of Q1 2016.

  • Russell Frank Company held 14,139 shares of Stemline Therapeutics, Inc. worth $66K as of Q1 2016.
  • Stemline Therapeutics, Inc. was a new Russell Frank Company position in Q1 2016.
  • Stemline Therapeutics, Inc. made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2833 holding.
  • Russell Frank Company first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and has held it in 3 quarters since.
  • Russell Frank Company's Stemline Therapeutics, Inc. position peaked at $775K in Q3 2013.
  • 63 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.